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Abstract  
Introduction 
The 4-tiered Peritoneal Regression Grading Score (PRGS) is assessing response to 
chemotherapy in peritoneal metastasis (PM). The PRGS is for example used to 
assess response to Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). 
However, the reproducibility of the PRGS is currently unkown. We aimed to evaluate 
the interobserver and intraobserver variability of the PRGS. 
Materials and methods 
33 patients who underwent at least 3 PIPAC treatments as part of the PIPAC-OPC1 
or PIPAC-OPC2 clinical trials at Odense University Hospital, Denmark, were 
included. Prior to each therapy cycle, peritoneal quadrant biopsies were obtained, 
and three H&E stained step sections were scanned and uploaded to a 
pseudonymized web library. For determining the interobserver variability, eight 
pathologists assessed the PRGS for each quadrant biopsy, and Krippendorff’s alpha 
and Intraclass Correlation Coefficients (ICCs) were calculated. For determining 
intraobserver variability, three pathologists repeated their own assessments, and 
Cohen’s kappa and ICCs were calculated. 
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Results 
A total of 331 peritoneal biopsies were analyzed. Interobserver variability for PRGS 
of each biopsy and for the mean and maximum PRGS per biopsy set was moderate 
to good/substantial. The intraobserver variability for PRGS of each biopsy and for the 
mean and maximum PRGS per biopsy set was good to excellent/almost perfect. 
Discussion 
Our data support the Peritoneal Regression Grading Score (PRGS) as a 
reproducible and useful tool to assess response to intraperitoneal chemotherapy in 
peritoneal metastasis. Future studies should evaluate the prognostic and predictive 
role of the PRGS. 
Keywords: colorectal cancer, gastric cancer, interobserver variability, ovarian 
cancer, pancreatic cancer, peritoneal metastasis, pressurized intraperitoneal aerosol 
chemotherapy (PIPAC), tumor regression grading 
Introduction 
Despite of the development of new molecular techniques, histological assessment 
remains the gold standard in the diagnosis of most human malignancies. The effect 
of treatment (e.g., chemotherapy) on the malignant tumor tissue – in the primary 
tumor as well as in its metastases - is assessed by histological characteristics like 
fibrosis, acellular mucin pools, hyalinosis, and/or infarct-like necrosis, resulting in a 
relative reduction of viable tumor cells 1. Hence, these regressive features can be 
used to identify subpopulations of patients who are most likely to benefit from a given 
therapy. Most published scoring systems for the assessment of the histological 
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response to neoadjuvant treatment are based on surgical resection specimens of the 
primary tumor or metastases 2-7. In 2016, the 4-tiered Peritoneal Regression Grading 
Score (PRGS) for the histological assessment of response to therapy in peritoneal 
metastasis (PM) was proposed by a group of European pathologists 8. The PRGS 
score is potentially clinically important in the assessment of histological response to 
intraperitoneal chemotherapy, particularly when such a therapy is given several 
times and the decision whether the patient should receive additional treatments 
depends on the histological response. A novel example of such a treatment is the 
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC), where 
chemotherapeutics are aerosolized within the peritoneal cavity during a standard 
laparoscopy at a capnoperitoneum 9-11. Currently, PIPAC is an experimental 
treatment, and randomized, controlled trials are lacking at present 12, 13. However, 
PIPAC seems to be a safe procedure, able to induce objective histological 
regression, to improve quality of life, and to result in improved survival 14-18. The 
interobserver and intraobserver variability in assessing the PRGS in PM as well as 
its prognostic or predictive value are not known. However, the accuracy of current 
imaging systems for detection and therapy response assessment of PM is limited, 
and the PRGS is gaining rapidly clinical acceptance 17-21.  
In this study, we evaluated the reproducibility of the PRGS in PM. Specific questions 
were the interobserver variability, the intraobserver variability, possible changes in 
the accuracy during the course of therapy, and the reproducibility of the maximal 
regression score vs. the mean regression score. Our study included peritoneal 
biopsies with PM deriving from a wide range of different primary tumors, scored by a 
group of pathologists with varying experience. 
This article is protected by copyright. All rights reserved. 
Methods 
Study design 
We performed an observational, retrospective, longitudinal, single-blinded study. The 
study has been approved by the Data Protection Agency of the Region of Southern 
Denmark (17/30427). One pathologist from each participating center signed a Data 
Processor Agreement, issued by the Data Protection Agency of the Region of 
Southern Denmark. All patients were part of the PIPAC-OPC1 (NCT02320448, 
n=27) or PIPAC-OPC2 (EudraCT provided, GCP monitored (EudraCT 2016-003394-
18), n=6) clinical trials, approved by the Ethics Committee of the Region of Southern 
Denmark (S-20140211, S-20160100). 
All peritoneal biopsies were obtained from 33 patients with PM treated at Odense 
PIPAC Centre (OPC), Odense University Hospital, Denmark, during the course of 
repeated Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) cycles. Based 
on current evidence, patients with PM of colorectal or appendiceal origin were 
treated with oxaliplatin 92 mg/m2 in 150 ml dextrose, while patients with PM of other 
origin were treated with a combination of cisplatin 7.5 mg/m2 in 150 ml saline and 
doxorubicin 1.5 mg/ m2 in 50 ml saline 18. A total of 331 peritoneal biopsies were 
evaluated, with three step sections per biopsy, resulting in a total of 993 step 
sections. The included patients had PM deriving from different primary tumors of 
different origin (Table 1). 
Peritoneal biopsy specimens 
All patients included in this study underwent at least three PIPAC procedures, and 
from all included patients, peritoneal quadrant biopsies taken prior to each PIPAC 
procedure were included. According to current recommendations, biopsies were 
This article is protected by copyright. All rights reserved. 
taken from macroscopically tumor suspect areas in all four abdominal quadrants, if 
technically possible. In some instances, however, only 1, 2 or 3 peritoneal biopsies 
could be taken for technical reasons. After obtaining the first set of biopsies prior to 
PIPAC treatment 1, the biopsy sites were marked with metal clips to ensure that 
subsequent biopsies were collected from the same sites. In order to ensure optimal 
fixation for reliable histopathological analysis, biopsies were fixed in 10% buffered 
formalin for 24–48 hours. Then, samples were embedded in paraffin using a 
controlled temperature. Two series of three 4-5 µm thick step sections from each 
biopsy were stained with hematoxylin and eosin (H&E) at the Department of 
Pathology, Odense University Hospital (OUH), Denmark. 
Web library 
All quantitative evaluation was performed on digitalized H&E stained slides. From the 
two available H&E stained step sections, the slide with the greater tissue area was 
scanned using a 20x objective on the NanoZoomer 2.0HT whole slide scanner 
(Hamamatsu Photonics, Hamamatsu, Japan). The digitalized slides were uploaded 
to a pseudonymized web library. Each pathologist participating in this study received 
a personalized code to access the web library, and each access to the web library 
was logged. 
Pathologists 
All slides were analyzed online by eight independent pathologists from different 
institutes, different countries and with diverse levels of practical experience in the 
assessment of histological regression grading in PM.  Four of the participating 
pathologists were co-authors of the proposal article regarding the PRGS 8. The other 
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four pathologists were trained to get familiar with the PRGS system and were given a 
copy of the reference publication 8. Besides, the untrained observers were taught to 
use the histological criteria of regression. Five pathologists were senior consultants, 
3 of whom had a special research interest in peritoneal pathology for >10 years, and 
three pathologists were residents in pathology with 2, 3, and 5 years of working 
experience in pathology. All eight pathologists were involved in the assessment of 
interobserver variability and assigned a PRGS score to each slide under 
investigation. Three pathologists (two senior consultants and one resident) repeated 
their own assessment, with 5, 10 and 12 weeks between the assessments, for 
determining the intraobserver variability. 
Peritoneal Regression Grading Score (PRGS) 
The PRGS defines four categories, based on the presence of residual tumor cells 
and the extent of regressive features. Major histological features of regression are 
fibrosis, inflammation, hyalinosis, acellular mucin pools, ischemic necrosis, 
accumulation of macrophages / multinucleated giant cells, and granulomas 8. PRGS 
1 corresponds to a complete regression with absence of tumor cells (Figure 1A-B); 
PRGS 2 to a major histological response with regressive features predominant over 
residual tumor cells (Figure 1C); PRGS 3 to a minor histological response with 
predominance of residual tumor cells over regressive features (Figure 1D); and 
PRGS 4 to a lack of histological response to therapy where the tumor cells are not 
accompanied by any regressive features (Figure 1E-H)8. According to the proposal, 
a PRGS was assessed for each quadrant biopsy. Moreover, the mean PRGS, based 
on the individual scores from the four quadrant biopsies, was given. 
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Statistics 
In order to determine the interobserver and intraobserver reproducibility, the 
statistical question is how reliable the measurements are. Reliability is defined as the 
extent to which measurements can be replicated 22. For evaluating the interobserver 
agreement between multiple raters, Krippendorff’s alpha using ordinal data was 
calculated. Krippendorff’s alpha can be used with any sample size, number of 
observers, and kind of data in addition to handling missing data appropriately. For 
evaluating the intraobserver agreement, Cohen’s kappa was used. Cohen’s kappa 
and Krippendorff’s alpha take coefficients ranging from 0 (or <0 in extreme cases) to 
1. A coefficient of 0 is indicative of no agreement and a coefficient of 1 represents
perfect agreement. Coefficients below 0 indicate poor/systematic disagreement, a 
coefficient between 0 and 0.2 slight agreement, between 0.21 and 0.40 fair, between 
0.41 and 0.60 moderate, between 0.61 and 0.80 substantial, and between 0.81 and 
1.0 almost perfect agreement. 
In addition to the calculations above, Intraclass Correlation Coefficients (ICCs) were 
calculated for interobserver variability and intraobserver variability. ICC is a reliability 
index that reflects both degree of correlation and agreement between 
measurements. It has been widely used in conservative care medicine to evaluate 
interobserver, test-retest, and intraobserver reliability of numerical or continuous 
measurements. For the interobserver variability, the ICCs were reported with 95% 
confidence intervals based on a single rater, absolute-agreement, using the two-way 
random-effects model. For the intraobserver variability, the ICCs were reported with 
95% confidence intervals based on a single rater, absolute agreement, using the 
two-way mixed-effects model. ICCs less than 0.5 are indicative of poor reliability, 
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ICCs between 0.5 and 0.75 indicate moderate reliability, ICCs between 0.75 and 0.9 
indicate good reliability, and ICCs greater than 0.90 indicate excellent reliability. 
The statistical analyses were performed using Stata v. 15 (StataCorp LLC, College 
Station, Texas), with the addition of kappaetc (Daniel Klein, INCHER-Kassel, 
University of Kassel, Germany) to calculate Krippendorff’s Alpha as well as Cohens 
Kappa. 
Results  
A total of 331 slides from 33 patients were prepared for evaluation. There were 106, 
112 and 113 slides from PIPAC 1, 2, and 3. All but 6 slides were rated by all 8 
pathologists. Altogether, 2642 ratings were performed. The combined gradings from 
all pathologists at the different time points (i.e. PIPAC treatments) is shown in Table 
2, demonstrating increasing frequency of lower PRGS scores from PIPAC 1 to 
PIPAC 3 (p < 0.001). 
The interobserver variability for the PRGS of each quadrant biopsy (Table 3) as well 
as for the mean (Table 4) and maximum (Table 5) PRGS per quadrant biopsy set 
are given. The ICC ranged from 0.63 and 0.76, indicating a moderate to good 
reliability. The Krippendorff’s alpha coefficients ranged from 0.60 to 0.74 regarding 
each quadrant biopsy score and the mean score per biopsy set (Table 3 & 4), 
indicating a substantial agreement. The agreement regarding the maximum PRGS 
per biopsy set was slightly worse, with Krippendorff’s alpha coefficients ranging from 
0.57 to 0.63, meaning moderate to substantial agreement. The difference between 
the mean PRGS per quadrant biopsy set from each single pathologist and the 
average mean PRGS per quadrant biopsy set from all eight pathologists’ scorings is 
visualized in Figure 2A. Likewise, the difference between the PRGS for each 
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quadrant biopsy from each single pathologist and the average PRGS for each 
quadrant biopsy, calculated from all eight pathologists’ scorings, is visualized in 
Figure 2B. These differences were normally distributed, and the large majority of 
scorings did not differ more than 0.5 PRGS from the mean values. Even though the 
PRGS was decreasing from PIPAC 1 to PIPAC 3, the reliability did not deteriorate 
over time and was not modified by increased regression. Figure 1 gives histological 
examples of cases where there was high agreement between the participating 
pathologists. 
The intraobserver variability for the PRGS of each quadrant biopsy (Table 6) as well 
as for the mean (Table 7) and maximum (Table 8) PRGS per quadrant biopsy set 
are given. The ICC varied between 0.87 and 1.00, reflecting good to excellent intra-
observer reproducibility. Kappa coefficients varied from 0.89 to 0.98, indicating 
almost perfect agreement. 
Table 9 shows the interobserver variability between groups at PIPAC no. 1 and 2. 
We compared senior consultants (n=5) with residents (n=3) and “authors of the 
proposal article” with “others”. In Table 10, agreement regarding the scoring of the 
first 33% of the biopsies at each PIPAC was compared with the agreement regarding 
the last 67% among all pathologists (n=8). 
Discussion 
In this observational, retrospective, longitudinal, single-blinded study, we found that 
the reproducibility of the PRGS for assessing histological response of PIPAC of PM 
is substantial. A total of 331 quadrant biopsies obtained from 33 patients with PM 
This article is protected by copyright. All rights reserved. 
taken at three different time points (prior to PIPAC treatment 1, 2 and 3) were 
evaluated. The interobserver agreement was moderate to good / substantial, and 
slightly better regarding the assessment of the mean PRGS per biopsy set compared 
to the maximum PRGS per biopsy set. When comparing the agreement between 
groups, residents had a slightly better agreement than senior consultants, and 
“others” had a slightly better agreement than the authors of the article proposing the 
PRGS 8. The intraobserver agreement was good to excellent / almost perfect. We 
found no training effect when comparing the agreement at the first 33% percent of 
the scored biopsies with the remaining 67%. 
The results of this study are encouraging, particularly when bearing in mind that the 
participating pathologists had less clinical information than in the clinical setting. 
First, they did not have access to immunohistochemistry. Second, they did not have 
access to microscopic slides from the primary tumors. Third, the participating 
pathologists were blinded regarding prior to which PIPAC treatment the biopsies 
were taken. Although the mean PRGS decreased from PIPAC 1 to PIPAC 3, there 
was no change in the accuracy during the course of therapy. Thus, our study 
supports that the PRGS is a reproducible and useful tool to assess response to 
intraperitoneal chemotherapy in PM. 
Most regression grading systems published so far do not require complementary 
immunohistochemical analysis. However, immunohistochemistry is an important 
adjunct in routine practice of clinical pathology. In the setting of PRGS, 
immunohistochemistry might allow identification of isolated tumor cells in inflamed 
scar tissue or clusters of tumor cells in heavily inflamed tissue that could not be 
visualized by H&E staining.  Thus, it is likely that the reproducibility of the PRGS 
would have been higher if the pathologists participating in the present study had had 
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access to immunohistochemistry. This may explain why one pathologist scored 
PRGS 2 instead of PRGS 1 in Figure 1A, and probably also why one pathologist 
scored PRGS 1 instead of PRGS 2 in Figure 1B. But also for the differentiation of 
PRGS 3 from PRGS 4 immunohistochemistry seems to be a useful tool, as 
illustrated in Figures 1E-H. We do not know whether the higher agreement between 
„others“ compared to agreement between the co-authors of the PRGS proposal 
article and, regarding the biopsies taken at PIPAC 1, the slightly higher agreement 
between residents compared to agreement between senior consultants means that 
these scores are more correct 8. It may, however, be speculated that the pathologists 
primarily not related to the PRGS development used the proposed PRGS criteria 
more stringently and categorically, while the scoring of pathologists who were 
involved in the PRGS proposal may have depended a bit more on their subjective 
opinion. 
For a long time, it has been acknowledged that the degree of histological regression 
may give clues to the effectiveness of chemotherapy for a given tumor. Several 
histological tumor regression systems (TRGs) have been developed for the 
quantification of response to chemotherapy of various primary and metastatic 
cancers. The Mandard system, developed for esophageal cancer and published in 
1994, was later on used in a wide range of other primary malignancies 5. Examples 
of TRG systems for rectal cancer are the Dworak (1997) and Rödel (2005) systems, 
and for colorectal liver metastases, the Rubbia-Brandt system (2007) 4, 6, 7. In 2014, 
Trakarnsanga et al. compared the concordance indices of four different TRGs 
(Mandard (3- and 5-category), Dworak/Rödel (3- and 5-category), Memorial Sloan 
Kettering Cancer Center (3-category) and American Joint Committee on Cancer and 
College of American Pathologists (AJCC/CAP) (4-category) in a cohort of 563 
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patients with locally advanced rectal cancer and concluded that the 4-category 
AJCC/CAP TRG was the most accurate and should be adopted as the standard 4, 5, 7,
23-26. For gastric cancer, six different TRG systems have been proposed so far, 
including the results of a recent Delphi survey 2, 27-31. Recently, a six-tiered and a 
condensed three-tiered chemotherapy response score (CRS) for tuboovarian high-
grade serous carcinoma after neoadjuvant chemotherapy and interval debulking 
surgery has been proposed and proved high reproducibility with a Kappa coefficient 
of 0.76 when using the condensed 3-tiered system 3, 32.  
Tumor response of PM from colon cancer was explored in terms of tumor growth and 
histology in tumor-bearing rats treated with hyperthermic intraperitoneal 
chemotherapy 33. The mean number of apoptotic cells and bodies in the entire 
cancer cell population was determined by counting their numbers in 5 high-power 
fields of non-necrotic areas. The index represented the number of visible apoptotic 
cancer cells in these fields. In the clinical setting, the histological response in 
patients with PM from colorectal cancer (n=144) treated with preoperative systemic 
chemotherapy was examined by determination of the percentage of viable tumor 
cells with respect to the area of each nodule 34. The assessment was independent of 
the presence of chemotherapy-related tissue injury, fibrosis, or necrosis. In gastric 
cancer patients, a four-category classification system was used to examine the 
histologic effects of neoadjuvant bidirectional intraperitoneal-systemic chemotherapy 
on primary tumors and PM nodules 35.  
Regardless of the approach used to quantify tumor response after neoadjuvant 
therapy, there is an urgent need for an objective, practical, reproducible and clinically 
relevant regression grading system for PM with acceptable interobserver and 
intraobserver variability. To our knowledge, the PRGS is the first biopsy-based 
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scoring system focusing on the assessment of histological response in the palliative 
setting in PM 8. The fact that we included PM from a wide range of different primary 
malignancies, that all biopsies were taken by the same team of surgeons and 
processed at the same pathological department should be considered a strength. To 
date, the clinical value of the PRGS has not been fully elucidated, but several clinical 
trials using the PRGS as primary or secondary outcome are currently ongoing 21, 36. 
Besides, a few studies reported a reduction of the mean PRGS after PIPAC 
treatment in 67-80% of the patients 17, 18, 37. Besides, initial data indicate a trend for 
prognostic significance of the PRGS 37. It is currently not known whether the mean 
PRGS or the maximum PRGS bears the highest clinical value.  
In conclusion, our study shows that the Peritoneal Regression Grading Score 
(PRGS) has moderate to good / substantial interobserver variability and good to 
excellent / almost perfect intraobserver variability for the assessment of response to 
treatment of peritoneal metastasis. Our study also shows that PRGS can be used by 
younger pathologists without loss of accuracy. Future studies should address the 
prognostic and predictive role of the PRGS in peritoneal metastasis. 
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Tables 
Table 1. Demographic data and baseline characteristics regarding the patients 
included in this study. 
Age, years (range) 62 (41-85) 
Sex, male / female 15 / 18 
Previous treatment 
Palliative SC 
No palliative SC 3 
One line palliative SC 23 
Two lines palliative SC 7 
> Two lines palliative SC 0 
Combination PIPAC / SC 6 
Primary tumor origin 
Colorectal adenocarcinoma 12* 
Pancreatic adenocarcinoma 4 
Gastric adenocarcinoma 4# 
Serous ovarian adenocarcinoma 4 
Appendix 4£ 
Malignant mesothelioma, epitheloid 
type 
1 
Small bowel adenocarcinoma 
(duodenum, jejunum) 
2 
Metastasis of unknown primary (MUP), 
adenocarcinoma 
1 
Extrahepatic bile ducts, 
adenocarcinoma  
1 
Peritoneal Cancer Index (PCI) 
PCI when ≥ 11 regions evaluated, 
mean (SD), n=26 
15.5 (11.7) 
PCI when < 11 regions evaluated, 
mean (SD), n=7 
6 (4.0) 
PCI, total (SD), n=33 13.5 (11.2) 
Ascites volume 
0 ml 22 
1 – 500 ml 5 
501 – 1000 ml 3 
> 1000 ml 3 
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* Hereof, three mucinous adenocarcinomas. # Hereof, one diffuse adenocarcinoma.
£ Three low-grade appendiceal mucinous neoplasms (LAMNs) and one mucinous 
adenocarcinoma.  
Table 2. Combined grading of the Peritoneal Regression Grading Score (PRGS) 
from all pathologists prior to the different PIPAC treatments. A total of 2642 scorings 
were performed. All grades were used at all time points, even though PRGS 4 was 
relative rarely used. There was an increasing frequency of lower PRGS scores from 
PIPAC 1 to PIPAC 3 (p<0.001). 
PRGS PIPAC no. 1 PIPAC no. 2 PIPAC no. 3 Total 
1 306 432 488 1226 
2 299 324 260 883 
3 185 120 129 434 
4 59 16 24 99 
Total 849 892 901 2642 
Table 3. Interobserver variability of the Peritoneal Regression Grading Score 
(PRGS) for scoring each quadrant biopsy.  
8 unique raters 
Time 
point 
N ICC 95% CI Krippendorff 
Alpha 
95% CI 
PIPAC 
no. 1 
106 0.70 0.63-0.76 0.66 0.59-0.73 
PIPAC 
no. 2 
108 0.64 0.56-0.71 0.60 0.53-0.66 
PIPAC 
no. 3 
110 0.64 0.57-0.71 0.60 0.54-0.66 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way random-effects model. 
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Table 4. Interobserver variability for rating the mean Peritoneal Regression Grading 
Score (PRGS) per quadrant biopsy set. 
8 unique raters 
Time point N ICC 95% CI Krippendorff 
Alpha 
95% CI 
PIPAC no. 1 33 0.76 0.65-0.85 0.74 0.65-0.85 
PIPAC no. 2 32 0.69 0.56-0.81 0.68 0.61-0.75 
PIPAC no. 3 33 0.71 0.60-0.82 0.71 0.60-0.82 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way random-effects model. 
Table 5. Interobserver variability for rating the maximum Peritoneal Regression 
Grading Score (PRGS) per quadrant biopsy set. 
8 unique raters 
Time point N ICC 95% CI Krippendorff 
Alpha 
95% CI 
PIPAC no. 1 33 0.65 0.52-0.77 0.59 0.43-0.76 
PIPAC no. 2 32 0.68 0.54-0.80 0.63 0.54-0.71 
PIPAC no. 3 33 0.63 0.50-0.76 0.57 0.47-0.67 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way random-effects model. 
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Table 6. Intraobserver variability for scoring the Peritoneal Regression Grading 
Score (PRGS) for each quadrant biopsy.  
PIPAC no. 1 
Observer N ICC 95% CI Kappa 95% CI 
A 106 0.93 0.90-0.95 0.92 0.86-0.98 
B 106 0.98 0.98-0.99 0.98 0.96-1.00 
C 106 0.89 0.85-0.93 0.89 0.80-0.97 
PIPAC no. 2 
Observer N ICC 95% CI Kappa 95% CI 
A 112 0.96 0.94-0.97 0.95 0.90-0.99 
B 112 0.98 0.97-0.98 0.97 0.94-1.00 
C 108 0.90 0.86-0.93 0.89 0.80-0.99 
PIPAC no. 3 
Observer N ICC 95% CI Kappa 95% CI 
A 112 0.96 0.94-0.97 0.95 0.90-0.99 
B 113 0.96 0.94-0.97 0.94 0.91-0.00 
C 111 0.86 0.80-0.90 0.84 0.75-0.92 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way mixed-effects model. 
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Table 7. Intraobserver variability for scoring the mean Peritoneal Regression 
Grading Score (PRGS) per quadrant biopsy set. 
PIPAC no. 1 
Observer N ICC 95% CI Kappa 95% CI 
A 33 0.94 0.88-0.97 0.92 0.85-0.98 
B 33 1.00 1.00-1.00 0.99 0.98-1.00 
C 33 0.96 0.92-0.98 0.95 0.92-1.00 
PIPAC no. 2 
Observer N ICC 95% CI Kappa 95% CI 
A 33 0.96 0.93-0.98 0.95 0.88-1.00 
B 33 1.00 1.00-1.00 0.99 0.98-1.00 
C 32 0.87 0.75-0.93 0.88 0.71-1.00 
PIPAC no. 3 
Observer N ICC 95% CI Kappa 95% CI 
A 33 0.96 0.92-0.98 0.96 0.92-1.00 
B 33 0.97 0.95-0.99 0.95 0.90-1.00 
C 33 0.93 0.87-0.97 0.92 0.85-0.98 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way mixed-effects model. 
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Table 8. Intraobserver variability for scoring the maximum PRGS per quadrant 
biopsy set. 
PIPAC no. 1 
Observer N ICC 95% CI Kappa 95% CI 
A 33 0.96 0.92-0.98 0.95 0.88-1.00 
B 33 1.0 * 1.00 1.00-1.00 
C 33 0.91 0.82-0.95 0.90 0.75-1.00 
PIPAC no. 2 
Observer N ICC 95% CI Kappa 95% CI 
A 33 1.0 * 1.00 1.00-1.00 
B 33 0.96 0.91-0.98 0.94 0.88-1.00 
C 32 0.98 0.95-0.99 0.97 0.89-1.00 
PIPAC no. 3 
Observer N ICC 95% CI Kappa 95% CI 
A 33 0.93 0.87-0.97 0.91 0.81-1.00 
B 33 0.96 0.93-0.98 0.95 0.89-1.00 
C 33 0.85 0.72-0.92 0.82 0.67-0.96 
ICC: Intraclass correlation coefficient. The given values are based on a single rater, 
absolute-agreement, 2-way mixed-effects model. *: complete agreement 
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Table 9. Interobserver variability between groups for scoring the mean PRGS per 
quadrant biopsy set at PIPAC no. 1 and PIPAC no.  2. The following groups were 
compared: Senior consultants (n=5) vs. residents (n=3) and “authors of the proposal 
article” (n=4) vs. “others” (n=4).  
PIPAC no. 1 
Groups of 
observers 
Number 
of 
observers 
N ICC 95% CI Krippendorff 
Alpha 
95% CI 
Senior 
consultants 
5 33 0.73 0.59-
0.84 
0.72 0.61-
0.83 
Residents 3 33 0.81 0.69-
0.90 
0.79 0.68-
0.90 
Proposal 
authors 
4 33 0.71 0.54-
0.83 
0.69 0.58-
0.81 
Others 4 33 0.84 0.74-
0.91 
0.82 0.71-
0.94 
PIPAC no. 2 
Groups of 
observers 
Number 
of 
observers 
N ICC 95% CI Krippendorff 
Alpha 
95% CI 
Senior 
consultants 
5 32 0.7 0.55-
0.82 
0.69 0.60-
0.78 
Residents 3 33 0.66 0.46-
0.80 
0.61 0.50-
0.72 
Proposal 
authors 
4 33 0.66 0.50-
0.80 
0.66 0.57-
0.74 
Others 4 32 0.74 0.58-
0.86 
0.72 0.60-
0.83 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way random-effects model. 
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Table 10. Training effect for scoring the mean PRGS per quadrant biopsy at PIPAC 
no. 1, 2 and 3. Level of agreement at each PIPAC divided between the first 33% and 
last 67% of the biopsies. 
Order of 
scorings 
N ICC 95% CI Krippendorff 
Alpha 
95% CI 
PIPAC no. 1 
First 33% 35 0.67 0.55-0.79 0.62 0.48-
0.76 
Last 67% 71 0.71 0.63-0.78 0.67 0.59-
0.74 
PIPAC no. 2 
First 33% 34 0.73 0.62-0.84 0.68 0.53-
0.83 
Last 67% 71 0.59 0.50-0.69 0.56 0.49-
0.62 
PIPAC no. 3 
First 33% 32 0.6 0.46-0.74 0.57 0.44-
0.70 
Last 67% 74 0.66 0.58-0.75 0.61 0.54-
0.68 
ICC: Intraclass correlation coefficient. The given coefficients are based on a single 
rater, absolute-agreement, 2-way random-effects model. 
Legends 
Figure 1. Histological examples of peritoneal biopsy specimens where there was 
relatively high (A-D) or relatively low (E-H) agreement between the participating 
pathologists. A. Peritoneal metastasis (PM) from gastric adenocarcinoma, PRGS 1. 
Seven pathologists scored PRGS 1 and one pathologist scored PRGS 2 (H&E). B. 
Peritoneal metastasis (PM) from colorectal mucinous adenocarcinoma, PRGS 1. 
Seven pathologists scored PRGS 1 and one pathologist scored PRGS 2 (H&E). C. 
PM from colorectal adenocarcinoma, PRGS 2. Seven pathologists scored PRGS 2 
and one pathologist scored PRGS 1 (H&E). D. PM from colorectal adenocarcinoma, 
PRGS score 3. Seven pathologists scored PRGS 3 and one pathologist scored 
PRGS 2. E. PM from ovarian serous adenocarcinoma, high grade, PRGS 4. Four 
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pathologists scored PRGS 4, three pathologists scored PRGS 3 and one pathologist 
scored PRGS 2 (H&E). F. Serial section of biopsy shown in Figure 1E, with 
immunohistochemical (IHC) staining of Ep-CAM, highlighting the numerous cancer 
cells present. IHC would probably have improved the interobserver agreement in this 
case. G. PM from gastric adenocarcinoma, PRGS 4. Five pathologists scored PRGS 
4 and three pathologists scored PRGS 3 (H&E). H. Serial section of biopsy shown in 
Figure 1G, with IHC of Ep-CAM, highlighting the numerous cancer cells. There are 
no clear-cut features of regression. 
Figure 2. Interobserver variability among eight pathologists assessing the PRGS in 
peritoneal metastasis (PM). A. The difference between the mean PRGS per 
quadrant biopsy set from each single pathologist and the average mean PRGS per 
quadrant biopsy set from all eight pathologists’ scorings (792 plotted values). B. The 
difference between the PRGS for each quadrant biopsy from each single pathologist 
and the average PRGS for each quadrant biopsy, calculated from all eight 
pathologists’ scorings (2642 plotted values). 
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